SAN CARLOS, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. [NASDAQ: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the second quarter of 2020 and filed its quarterly report on Form 10-Q for the three and six months […]
Financial
Caladrius Biosciences Provides Corporate Update and Reports 2020 Second Quarter Financial Results
Clinical programs advanced and expanded with strengthened cash position Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Aug. 13, 2020 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not […]
Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2021
On track to report TRILOGY 2 topline data on or about August 31, 2020 LAVAL, Québec, Aug. 13, 2020 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® […]
scPharmaceuticals Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update
Preparations ongoing for December 30, 2020 FUROSCIX® PDUFA date BURLINGTON, Mass.–(BUSINESS WIRE)–scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the second quarter ended […]
PhaseBio Reports Recent Business Highlights and Second-Quarter 2020 Financial Results
Received FDA authorization to proceed with “VANGARD” clinical trial to assess the efficacy and safety of PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome (ARDS) and commenced dosing of patients MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage […]
BioVentrix Announces Appointment of Accredited Public Company Director Raymond W. Cohen to its Board of Directors
SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure via Transcatheter Ventricular Restoration (TCVR), today announced the appointment of Raymond W. Cohen to the Company’s board of directors. Mr. Cohen, an accredited public company director, has nearly 40 years of experience leading […]
Imricor Announces Sales Collaboration with Optoacoustics
MINNEAPOLIS–(BUSINESS WIRE)–Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR), the global leader in MRI-guided cardiac ablation products, is pleased to announce a sales collaboration with Optoacoustics Ltd, the world leader in innovative, high performance optical communication solutions for magnetic resonance (MR) applications. The collaboration establishes a formal relationship between Imricor and Optoacoustics to facilitate […]
Shockwave Medical Reports Second Quarter 2020 Financial Results
SANTA CLARA, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended June 30, 2020. Recent Highlights Recognized revenue of $10.3 million […]
Neovasc Announces Closing of US$12.6 Million Registered Direct Offering Priced At-The-Market
Vancouver, Canada, Aug. 12, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today that it has closed its previously announced registered direct offering (the “Offering”) priced at-the-market under the Nasdaq rules of an aggregate of 4,532,772 common shares at a […]
Medicure Reports Financial Results for Quarter Ended June 30, 2020
WINNIPEG, MB, Aug. 11, 2020 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company“) (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended June 30, 2020. Quarter Ended June 30, 2020 Highlights: Net income for the quarter ended June 30, 2020 was $19,000 compared to net loss of $957,000 for the quarter ended June 30, […]



